Systemic lupus erythematosus (SLE) is a multisystem disease with a complex etiology. Its
risk is higher among women, racial and ethnic minorities, and individuals with a family …

Environmental exposures and the development of systemic lupu... : Current Opinion in
Rheumatology Environmental exposures and the development of systemic lupus erythematosus …

Objective An international multidisciplinary initiative, jointly supported by the American
College of Rheumatology and European Alliance of Associations for Rheumatology, is …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Objective To develop an evidence‐based guideline on contraception, assisted reproductive
technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal …

Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for
systemic rheumatic diseases worldwide and is the recommended first-line agent for …

Objective The incidence of systemic lupus erythematosus (SLE) is disproportionately high in
nonwhite patients compared with white patients. However, variation in mortality according to …

Supplemental material This content has been supplied by the author (s). It has not been
vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any …

Objectives Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease,
subtyped according to clinical manifestations and autoantibodies. Evidence concerning …

Objectives To assess whether patients with antiphospholipid syndrome (APS) and history of
recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome …